Inasmuch as Eliquis’ PDUFA date is 6/28/12, the canceled meeting in May almost certainly means that Eliquis will not have an FDA advisory panel. Given the strength of the Eliquis data in both the ARISTOTLE (#msg-66604305, #msg-66610218) and AVERROES (#msg-54576974) studies, the cancellation of the advisory panel is presumably bullish.
Market Data 
Markets 
AI
